Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2014

Open Access 01-12-2014 | Research article

Plasma, salivary and urinary cortisol levels following physiological and stress doses of hydrocortisone in normal volunteers

Authors: Caroline Jung, Santo Greco, Hanh HT Nguyen, Jui T Ho, John G Lewis, David J Torpy, Warrick J Inder

Published in: BMC Endocrine Disorders | Issue 1/2014

Login to get access

Abstract

Background

Glucocorticoid replacement is essential in patients with primary and secondary adrenal insufficiency, but many patients remain on higher than recommended dose regimens. There is no uniformly accepted method to monitor the dose in individual patients. We have compared cortisol concentrations in plasma, saliva and urine achieved following “physiological” and “stress” doses of hydrocortisone as potential methods for monitoring glucocorticoid replacement.

Methods

Cortisol profiles were measured in plasma, saliva and urine following “physiological” (20 mg oral) or “stress” (50 mg intravenous) doses of hydrocortisone in dexamethasone-suppressed healthy subjects (8 in each group), compared to endogenous cortisol levels (12 subjects). Total plasma cortisol was measured half-hourly, and salivary cortisol and urinary cortisol:creatinine ratio were measured hourly from time 0 (between 0830 and 0900) to 5 h. Endogenous plasma corticosteroid-binding globulin (CBG) levels were measured at time 0 and 5 h, and hourly from time 0 to 5 h following administration of oral or intravenous hydrocortisone. Plasma free cortisol was calculated using Coolens’ equation.

Results

Plasma, salivary and urine cortisol at 2 h after oral hydrocortisone gave a good indication of peak cortisol concentrations, which were uniformly supraphysiological. Intravenous hydrocortisone administration achieved very high 30 minute cortisol concentrations. Total plasma cortisol correlated significantly with both saliva and urine cortisol after oral and intravenous hydrocortisone (P <0.0001, correlation coefficient between 0.61 and 0.94). There was no difference in CBG levels across the sampling period.

Conclusions

An oral dose of hydrocortisone 20 mg is supraphysiological for routine maintenance, while stress doses above 50 mg 6-hourly would rarely be necessary in managing acute illness. Salivary cortisol and urinary cortisol:creatinine ratio may provide useful alternatives to plasma cortisol measurements to monitor replacement doses in hypoadrenal patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Thomson AH, Devers MC, Wallace AM, Grant D, Campbell K, Freel M, Connell JM: Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2007, 66: 789-796. 10.1111/j.1365-2265.2007.02812.x.CrossRef Thomson AH, Devers MC, Wallace AM, Grant D, Campbell K, Freel M, Connell JM: Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2007, 66: 789-796. 10.1111/j.1365-2265.2007.02812.x.CrossRef
3.
go back to reference Kenny FM, Preeyasombat C, Migeon CJ: Cortisol production rate II Normal infants, children, and adults. Pediatrics. 1966, 37: 34-42.PubMed Kenny FM, Preeyasombat C, Migeon CJ: Cortisol production rate II Normal infants, children, and adults. Pediatrics. 1966, 37: 34-42.PubMed
4.
go back to reference Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC, Loriaux DL: Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991, 72: 39-45. 10.1210/jcem-72-1-39.CrossRefPubMed Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC, Loriaux DL: Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991, 72: 39-45. 10.1210/jcem-72-1-39.CrossRefPubMed
5.
go back to reference Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, Rogol AD: Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab. 1993, 76: 1505-1510.PubMed Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, Rogol AD: Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab. 1993, 76: 1505-1510.PubMed
6.
go back to reference Kraan GP, Dullaart RP, Pratt JJ, Wolthers BG, Drayer NM, De Bruin R: The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J Clin Endocrinol Metab. 1998, 83: 1247-1252.PubMed Kraan GP, Dullaart RP, Pratt JJ, Wolthers BG, Drayer NM, De Bruin R: The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J Clin Endocrinol Metab. 1998, 83: 1247-1252.PubMed
7.
go back to reference Crown A, Lightman S: Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf). 2005, 63: 483-492. 10.1111/j.1365-2265.2005.02320.x.CrossRef Crown A, Lightman S: Why is the management of glucocorticoid deficiency still controversial: a review of the literature. Clin Endocrinol (Oxf). 2005, 63: 483-492. 10.1111/j.1365-2265.2005.02320.x.CrossRef
8.
go back to reference Howlett TA: An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf). 1997, 46: 263-268. 10.1046/j.1365-2265.1997.1340955.x.CrossRef Howlett TA: An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol (Oxf). 1997, 46: 263-268. 10.1046/j.1365-2265.1997.1340955.x.CrossRef
9.
go back to reference Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM: ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab. 2009, 94: 4216-4223. 10.1210/jc.2009-1097.CrossRefPubMed Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates AS, Stewart PM: ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin Endocrinol Metab. 2009, 94: 4216-4223. 10.1210/jc.2009-1097.CrossRefPubMed
10.
go back to reference Arlt W, Rosenthal C, Hahner S, Allolio B: Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf). 2006, 64: 384-389. Arlt W, Rosenthal C, Hahner S, Allolio B: Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf). 2006, 64: 384-389.
11.
go back to reference Zueger T, Kirchner P, Herren C, Fischli S, Zwahlen M, Christ E, Stettler C: Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab. 2012, 97: E1938-E1942. 10.1210/jc.2012-2432.CrossRefPubMed Zueger T, Kirchner P, Herren C, Fischli S, Zwahlen M, Christ E, Stettler C: Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J Clin Endocrinol Metab. 2012, 97: E1938-E1942. 10.1210/jc.2012-2432.CrossRefPubMed
12.
go back to reference Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ: Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2006, 65: 45-50. 10.1111/j.1365-2265.2006.02544.x.CrossRef Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, Ross RJ: Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2006, 65: 45-50. 10.1111/j.1365-2265.2006.02544.x.CrossRef
13.
go back to reference Lovas K, Husebye ES: Continuous subcutaneous hydrocortisone infusion in Addison’s disease. Eur J Endocrinol. 2007, 157: 109-112. 10.1530/EJE-07-0052.CrossRefPubMed Lovas K, Husebye ES: Continuous subcutaneous hydrocortisone infusion in Addison’s disease. Eur J Endocrinol. 2007, 157: 109-112. 10.1530/EJE-07-0052.CrossRefPubMed
14.
go back to reference Newell-Price J, Whiteman M, Rostami-Hodjegan A, Darzy K, Shalet S, Tucker GT, Ross RJ: Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf). 2008, 68: 130-135. 10.1111/j.1365-2265.2007.03011.x.CrossRef Newell-Price J, Whiteman M, Rostami-Hodjegan A, Darzy K, Shalet S, Tucker GT, Ross RJ: Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone-suppressed normal volunteers. Clin Endocrinol (Oxf). 2008, 68: 130-135. 10.1111/j.1365-2265.2007.03011.x.CrossRef
15.
go back to reference Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ: Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab. 2009, 94: 1548-1554. 10.1210/jc.2008-2380.CrossRefPubMedPubMedCentral Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ: Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab. 2009, 94: 1548-1554. 10.1210/jc.2008-2380.CrossRefPubMedPubMedCentral
16.
go back to reference Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S: Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol. 2009, 161: 119-130. 10.1530/EJE-09-0170.CrossRefPubMed Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T, Skrtic S: Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol. 2009, 161: 119-130. 10.1530/EJE-09-0170.CrossRefPubMed
17.
go back to reference Russell GM, Durant C, Ataya A, Papastathi C, Bhake R, Woltersdorf W, Lightman S: Subcutaneous pulsatile glucocorticoid replacement therapy. Clin Endocrinol (Oxf). 2014, 81: 289-293. 10.1111/cen.12470.CrossRef Russell GM, Durant C, Ataya A, Papastathi C, Bhake R, Woltersdorf W, Lightman S: Subcutaneous pulsatile glucocorticoid replacement therapy. Clin Endocrinol (Oxf). 2014, 81: 289-293. 10.1111/cen.12470.CrossRef
18.
go back to reference Wong V, Yan T, Donald A, McLean M: Saliva and bloodspot cortisol: novel sampling methods to assess hydrocortisone replacement therapy in hypoadrenal patients. Clin Endocrinol (Oxf). 2004, 61: 131-137. 10.1111/j.1365-2265.2004.02062.x.CrossRef Wong V, Yan T, Donald A, McLean M: Saliva and bloodspot cortisol: novel sampling methods to assess hydrocortisone replacement therapy in hypoadrenal patients. Clin Endocrinol (Oxf). 2004, 61: 131-137. 10.1111/j.1365-2265.2004.02062.x.CrossRef
19.
go back to reference Ekman B, Fitts D, Marelli C, Murray RD, Quinkler M, Zelissen PM: European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy. BMC Endocr Disord. 2014, 14: 40-10.1186/1472-6823-14-40.CrossRefPubMedPubMedCentral Ekman B, Fitts D, Marelli C, Murray RD, Quinkler M, Zelissen PM: European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy. BMC Endocr Disord. 2014, 14: 40-10.1186/1472-6823-14-40.CrossRefPubMedPubMedCentral
20.
go back to reference Aanderud S, Myking OL: Plasma cortisol concentrations after oral substitution of cortisone in the fasting and non-fasting state. Acta Med Scand. 1981, 210: 157-161.CrossRefPubMed Aanderud S, Myking OL: Plasma cortisol concentrations after oral substitution of cortisone in the fasting and non-fasting state. Acta Med Scand. 1981, 210: 157-161.CrossRefPubMed
21.
go back to reference Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, Tucker GT, Ross RJ: Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2004, 61: 367-375. 10.1111/j.1365-2265.2004.02106.x.CrossRef Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, Tucker GT, Ross RJ: Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf). 2004, 61: 367-375. 10.1111/j.1365-2265.2004.02106.x.CrossRef
22.
23.
go back to reference Kehlet H, Binder C, Blichert-Toft M: Glucocorticoid maintenance therapy following adrenalectomy: assessment of dosage and preparation. Clin Endocrinol (Oxf). 1976, 5: 37-41. 10.1111/j.1365-2265.1976.tb03801.x.CrossRef Kehlet H, Binder C, Blichert-Toft M: Glucocorticoid maintenance therapy following adrenalectomy: assessment of dosage and preparation. Clin Endocrinol (Oxf). 1976, 5: 37-41. 10.1111/j.1365-2265.1976.tb03801.x.CrossRef
24.
go back to reference Feek CM, Ratcliffe JG, Seth J, Gray CE, Toft AD, Irvine WJ: Patterns of plasma cortisol and ACTH concentrations in patients with Addison’s disease treated with conventional corticosteroid replacement. Clin Endocrinol (Oxf). 1981, 14: 451-458. 10.1111/j.1365-2265.1981.tb00634.x.CrossRef Feek CM, Ratcliffe JG, Seth J, Gray CE, Toft AD, Irvine WJ: Patterns of plasma cortisol and ACTH concentrations in patients with Addison’s disease treated with conventional corticosteroid replacement. Clin Endocrinol (Oxf). 1981, 14: 451-458. 10.1111/j.1365-2265.1981.tb00634.x.CrossRef
25.
go back to reference Coolens JL, Van Baelen H, Heyns W: Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin. J Steroid Biochem. 1987, 26: 197-202. 10.1016/0022-4731(87)90071-9.CrossRefPubMed Coolens JL, Van Baelen H, Heyns W: Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin. J Steroid Biochem. 1987, 26: 197-202. 10.1016/0022-4731(87)90071-9.CrossRefPubMed
26.
go back to reference Maguire AM, Ambler GR, Moore B, Waite K, McLean M, Cowell CT: The clinical utility of alternative, less invasive sampling techniques in the assessment of oral hydrocortisone therapy in children and adolescents with hypopituitarism. Eur J Endocrinol. 2007, 156: 471-476. 10.1530/EJE-06-0700.CrossRefPubMed Maguire AM, Ambler GR, Moore B, Waite K, McLean M, Cowell CT: The clinical utility of alternative, less invasive sampling techniques in the assessment of oral hydrocortisone therapy in children and adolescents with hypopituitarism. Eur J Endocrinol. 2007, 156: 471-476. 10.1530/EJE-06-0700.CrossRefPubMed
27.
go back to reference Lovas K, Thorsen TE, Husebye ES: Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison’s disease. J Endocrinol Invest. 2006, 29: 727-731. 10.1007/BF03344183.CrossRefPubMed Lovas K, Thorsen TE, Husebye ES: Saliva cortisol measurement: simple and reliable assessment of the glucocorticoid replacement therapy in Addison’s disease. J Endocrinol Invest. 2006, 29: 727-731. 10.1007/BF03344183.CrossRefPubMed
28.
go back to reference Burch WM: Urine free-cortisol determination. A useful tool in the management of chronic hypoadrenal states. JAMA. 1982, 247: 2002-2004. 10.1001/jama.1982.03320390064047.CrossRefPubMed Burch WM: Urine free-cortisol determination. A useful tool in the management of chronic hypoadrenal states. JAMA. 1982, 247: 2002-2004. 10.1001/jama.1982.03320390064047.CrossRefPubMed
29.
go back to reference Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, Weetman AP: Glucocorticoid replacement therapy: are patients over treated and does it matter?. Clin Endocrinol (Oxf). 1997, 46: 255-261. 10.1046/j.1365-2265.1997.780907.x.CrossRef Peacey SR, Guo CY, Robinson AM, Price A, Giles MA, Eastell R, Weetman AP: Glucocorticoid replacement therapy: are patients over treated and does it matter?. Clin Endocrinol (Oxf). 1997, 46: 255-261. 10.1046/j.1365-2265.1997.780907.x.CrossRef
30.
go back to reference Jung C, Inder WJ: Management of adrenal insufficiency during the stress of medical illness and surgery. Med J Aust. 2008, 188: 409-413.PubMed Jung C, Inder WJ: Management of adrenal insufficiency during the stress of medical illness and surgery. Med J Aust. 2008, 188: 409-413.PubMed
31.
go back to reference Debono M, Ross RJ, Newell-Price J: Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol. 2009, 160: 719-729. 10.1530/EJE-08-0874.CrossRefPubMed Debono M, Ross RJ, Newell-Price J: Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol. 2009, 160: 719-729. 10.1530/EJE-08-0874.CrossRefPubMed
32.
go back to reference Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM: The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008, 93: 1526-1540. 10.1210/jc.2008-0125.CrossRefPubMedPubMedCentral Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM: The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008, 93: 1526-1540. 10.1210/jc.2008-0125.CrossRefPubMedPubMedCentral
33.
go back to reference Tunn S, Mollmann H, Barth J, Derendorf H, Krieg M: Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. Clin Chem. 1992, 38: 1491-1494.PubMed Tunn S, Mollmann H, Barth J, Derendorf H, Krieg M: Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. Clin Chem. 1992, 38: 1491-1494.PubMed
34.
go back to reference Aardal E, Holm AC: Cortisol in saliva–reference ranges and relation to cortisol in serum. Eur J Clin Chem Clin Biochem. 1995, 33: 927-932.PubMed Aardal E, Holm AC: Cortisol in saliva–reference ranges and relation to cortisol in serum. Eur J Clin Chem Clin Biochem. 1995, 33: 927-932.PubMed
35.
go back to reference Morgan SA, McCabe EL, Gathercole LL, Hassan-Smith ZK, Larner DP, Bujalska IJ, Stewart PM, Tomlinson JW, Lavery GG: 11beta-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proc Natl Acad Sci U S A. 2014, 111: E2482-E2491. 10.1073/pnas.1323681111.CrossRefPubMedPubMedCentral Morgan SA, McCabe EL, Gathercole LL, Hassan-Smith ZK, Larner DP, Bujalska IJ, Stewart PM, Tomlinson JW, Lavery GG: 11beta-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. Proc Natl Acad Sci U S A. 2014, 111: E2482-E2491. 10.1073/pnas.1323681111.CrossRefPubMedPubMedCentral
36.
go back to reference Smans L, Lentjes E, Hermus A, Zelissen P: Salivary cortisol day curves in assessing glucocorticoid replacement therapy in Addison’s disease. Hormones (Athens). 2013, 12: 93-100. Smans L, Lentjes E, Hermus A, Zelissen P: Salivary cortisol day curves in assessing glucocorticoid replacement therapy in Addison’s disease. Hormones (Athens). 2013, 12: 93-100.
37.
go back to reference Ho JT, Al-Musalhi H, Chapman MJ, Quach T, Thomas PD, Bagley CJ, Lewis JG, Torpy DJ: Septic shock and sepsis: a comparison of total and free plasma cortisol levels. J Clin Endocrinol Metab. 2006, 91: 105-114. 10.1210/jc.2005-0265.CrossRefPubMed Ho JT, Al-Musalhi H, Chapman MJ, Quach T, Thomas PD, Bagley CJ, Lewis JG, Torpy DJ: Septic shock and sepsis: a comparison of total and free plasma cortisol levels. J Clin Endocrinol Metab. 2006, 91: 105-114. 10.1210/jc.2005-0265.CrossRefPubMed
38.
go back to reference Widmer IE, Puder JJ, Konig C, Pargger H, Zerkowski HR, Girard J, Muller B: Cortisol response in relation to the severity of stress and illness. J Clin Endocrinol Metab. 2005, 90: 4579-4586. 10.1210/jc.2005-0354.CrossRefPubMed Widmer IE, Puder JJ, Konig C, Pargger H, Zerkowski HR, Girard J, Muller B: Cortisol response in relation to the severity of stress and illness. J Clin Endocrinol Metab. 2005, 90: 4579-4586. 10.1210/jc.2005-0354.CrossRefPubMed
39.
go back to reference Arafah BM: Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. J Clin Endocrinol Metab. 2006, 91: 3725-3745. 10.1210/jc.2006-0674.CrossRefPubMed Arafah BM: Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. J Clin Endocrinol Metab. 2006, 91: 3725-3745. 10.1210/jc.2006-0674.CrossRefPubMed
40.
go back to reference Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B: Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome–recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem. 1997, 34: 222-229. 10.1177/000456329703400302.CrossRefPubMed Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B: Evidence for the low dose dexamethasone suppression test to screen for Cushing’s syndrome–recommendations for a protocol for biochemistry laboratories. Ann Clin Biochem. 1997, 34: 222-229. 10.1177/000456329703400302.CrossRefPubMed
41.
go back to reference Taylor AE, Karavitaki N, Foster M, Meier S, O’Neil DM, Komninos J, Vassiliadi DM, Mowatt CJ, Lord JM, Wass JAH, Arlt W: Prevention of adrenal crisis in stress: serum cortisol during elective surgery, acute trauma surgery and during “stress dose cover” hydrocortisone replacement in adrenal insufficiency. ENDO. 2013, Poster abstract SAT-39 Taylor AE, Karavitaki N, Foster M, Meier S, O’Neil DM, Komninos J, Vassiliadi DM, Mowatt CJ, Lord JM, Wass JAH, Arlt W: Prevention of adrenal crisis in stress: serum cortisol during elective surgery, acute trauma surgery and during “stress dose cover” hydrocortisone replacement in adrenal insufficiency. ENDO. 2013, Poster abstract SAT-39
42.
go back to reference Heazelwood VJ, Galligan JP, Cannell GR, Bochner F, Mortimer RH: Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. Br J Clin Pharmacol. 1984, 17: 55-59. 10.1111/j.1365-2125.1984.tb04999.x.CrossRefPubMedPubMedCentral Heazelwood VJ, Galligan JP, Cannell GR, Bochner F, Mortimer RH: Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. Br J Clin Pharmacol. 1984, 17: 55-59. 10.1111/j.1365-2125.1984.tb04999.x.CrossRefPubMedPubMedCentral
43.
go back to reference Behan LA, Rogers B, Hannon MJ, O’Kelly P, Tormey W, Smith D, Thompson CJ, Agha A: Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients. Clin Endocrinol (Oxf). 2011, 75: 505-513. 10.1111/j.1365-2265.2011.04074.x.CrossRef Behan LA, Rogers B, Hannon MJ, O’Kelly P, Tormey W, Smith D, Thompson CJ, Agha A: Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients. Clin Endocrinol (Oxf). 2011, 75: 505-513. 10.1111/j.1365-2265.2011.04074.x.CrossRef
44.
go back to reference Barlow NL, Holme J, Stockley RA, Clark PM: An evaluation of measured and calculated serum free cortisol in a group of patients with known adrenal suppression. Ann Clin Biochem. 2010, 47: 200-204. 10.1258/acb.2010.009246.CrossRefPubMed Barlow NL, Holme J, Stockley RA, Clark PM: An evaluation of measured and calculated serum free cortisol in a group of patients with known adrenal suppression. Ann Clin Biochem. 2010, 47: 200-204. 10.1258/acb.2010.009246.CrossRefPubMed
Metadata
Title
Plasma, salivary and urinary cortisol levels following physiological and stress doses of hydrocortisone in normal volunteers
Authors
Caroline Jung
Santo Greco
Hanh HT Nguyen
Jui T Ho
John G Lewis
David J Torpy
Warrick J Inder
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2014
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/1472-6823-14-91

Other articles of this Issue 1/2014

BMC Endocrine Disorders 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.